Literature DB >> 1565813

Transpulmonary angiotensin II formation and pulmonary haemodynamics in stable hypoxic lung disease: the effect of captopril.

A J Peacock1, A Matthews.   

Abstract

The effect of chronic hypoxic lung disease on the activity of the renin-angiotensin (RA) system and the role the RA system plays in the pulmonary vascular changes that accompany hypoxia remain controversial. We have measured transpulmonary generation of angiotensin II (A II) and pulmonary haemodynamics in nine patients with airflow obstruction (mean FEV1 = 0.741) and arterial hypoxaemia (mean PaO2 = 8.4 Pa) before and after captopril. In each patient pulmonary artery pressure, cardiac output, systemic arterial pressure, arterial and mixed venous blood gas tensions and arterial and mixed venous A II were measured at rest and at intervals for a total of 3 h after 25 mg captopril orally. The patients had moderate pulmonary hypertension (mean = 29 mmHg) and slightly raised A II levels (mean = 47.2 pg ml-1) but no step-up in A II levels across the lung. After captopril, both arterial and mixed venous A II levels fell by, on average 80% (SEM 2%), but the transpulmonary gradient for A II remained unchanged for each subject. The systemic arterial pressure fell by an average 18% (SEM 5%). In seven patients pulmonary vascular resistance fell (mean = 31%, SEM 6%) and in two patients it rose. There was no significant change in blood gas tensions. These findings suggest that patients with chronic hypoxic lung disease have decreased conversion of A I to A II in the lung but stimulation of the extra-pulmonary renin-angiotensin system. ACE inhibition appears to cause a fall in PVR in most patients with severe chronic airflow obstruction without deterioration in gas exchange.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565813     DOI: 10.1016/s0954-6111(06)80143-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

Review 2.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

3.  Activity of the renin-angiotensin system in acute severe asthma and the effect of angiotensin II on lung function.

Authors:  E A Millar; R M Angus; G Hulks; J J Morton; J M Connell; N C Thomson
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

4.  Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study.

Authors:  Bradley A Maron; Thomas E Stephens; Laurie A Farrell; William M Oldham; Joseph Loscalzo; Jane A Leopold; Gregory D Lewis
Journal:  J Heart Lung Transplant       Date:  2015-10-19       Impact factor: 10.247

5.  The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study.

Authors:  Corey E Ventetuolo; Joao A C Lima; R Graham Barr; Michael R Bristow; Emilia Bagiella; Harjit Chahal; Jorge R Kizer; David J Lederer; David A Bluemke; Steven M Kawut
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

6.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Nicholas W Morrell; Matthew A Higham; Peter G Phillips; B Haleema Shakur; Paul J Robinson; Ray J Beddoes
Journal:  Respir Res       Date:  2005-08-01

7.  Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure.

Authors:  Hui-Jie Li; Cheng-Rong Zheng; Guo-Zhu Chen; Jun Qin; Ji-Hang Zhang; Jie Yu; En-Hao Zhang; Lan Huang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-06-17       Impact factor: 1.636

Review 8.  Angiotensin-converting enzyme 2 in lung diseases.

Authors:  Keiji Kuba; Yumiko Imai; Josef M Penninger
Journal:  Curr Opin Pharmacol       Date:  2006-04-03       Impact factor: 5.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.